RNAZ

Transcode Therapeutics, Inc. (RNAZ) - Q2 2025 Filing Summary

Business Context and Reporting Period

This Form 10-Q covers the quarterly period ended June 30, 2025. Transcode Therapeutics, Inc. is a clinical-stage biopharmaceutical company focused on developing RNA therapeutics for oncology. The company's lead candidate, TTX-MC138, targets miRNA-10b to inhibit metastatic tumor cell survival. The company has no approved products and has not generated revenue from product sales.

Key Financial Metrics

Material Changes vs. Prior Period

• Net Loss Increase: The net loss for the six months ended June 30, 2025, increased to $16.36 million from $8.52 million in the same period in 2024. This increase was primarily driven by a non-cash expense of $9.40 million related to the change in fair value of warrant liabilities (specifically Series D warrants exercised in Q1 2025).
• Operating Expense Reduction: Total operating expenses decreased by approximately $1.01 million year-over-year for the six-month period. This reduction reflects cost-cutting measures, including headcount reductions (to seven employees), termination of a sublease, and reduced insurance and legal fees.
• Grant Income: Grant income increased to $0.50 million for the six months ended June 30, 2025, compared to $0.03 million in 2024, due to the recognition of income from a new NIH SBIR Award received in September 2024.
• Equity Financing: The company raised approximately $8.85 million in net proceeds from the sale of common stock during the first half of 2025, including a March 2025 offering.
• Stock Split: A 1-for-28 reverse stock split was effected on May 15, 2025. All share data in the filing has been retroactively adjusted.

Outlook, Risks, and Management Commentary

• Liquidity and Going Concern: Management states there is substantial doubt about the company's ability to continue as a going concern. Cash on hand ($7.37 million) is estimated to fund operations only into the fourth quarter of 2025. Additional capital is required to fund clinical trials and operations beyond that date.
• Clinical Progress: The Phase I/II clinical trial for TTX-MC138 commenced in Q3 2024. As of the filing date, the Safety Review Committee has approved dosing for Cohorts 1 through 4, with no significant safety or dose-limiting toxicities reported. Preliminary PK/PD data is consistent with preclinical results.
• Restructuring: The company terminated its Newton, MA sublease and relocated to short-term space in Woburn, MA. R&D activities are being conducted in conjunction with Michigan State University. Headcount was reduced to seven employees.
• Key Risks:
  • Capital Requirements: Failure to raise additional capital could force the company to scale back operations, terminate development programs, or seek restructuring of liabilities.
  • Nasdaq Compliance: The company received notification of compliance with Nasdaq minimum bid price requirements as of June 2, 2025, but delisting remains a risk if compliance is not maintained.
  • Internal Controls: The company disclosed that its disclosure controls and procedures were not effective as of June 30, 2025, due to material weaknesses in internal control over financial reporting that remain unremediated.

Investor Verification Checklist

• Cash Runway: Verify the specific timeline for cash depletion and the status of any new financing discussions beyond Q4 2025.
• Warrant Liability: Confirm the status of remaining warrant liabilities and the impact of potential future fair value adjustments on net income.
• Clinical Trial Enrollment: Monitor patient enrollment rates and safety data for the TTX-MC138 Phase I/II trial to assess development timelines.
• Internal Control Remediation: Review future filings for progress on remediating the material weaknesses in internal controls over financial reporting.
• Grant Funding: Track the disbursement and utilization of the $2.0 million NIH SBIR Award received in late 2024.